WHO ICTRP trial
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the…
NL-OMON51883 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51883 |
|---|---|
| Public title | A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease |
| Scientific title | A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease - APD334-202EU (Cultivate) |
| Primary sponsor | Arena Pharmaceuticals, Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy… |
| Conditions | Crohn's disease;10017969;Crohn's disease |
| Interventions | Depending on the substudy the subject will be taking etrasimod 3 mg, etrasimod 2 mg or matching placebo. ;Crohn s Disease;Efficacy;Etrasimod;Safety |
| Registration date | Sep 15, 2022 |
| Target size | 9 |
| Secondary IDs | 2020-004775-40;NCT04173273;NL76169.056.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: